发明名称 mTOR mutants as biomarkers for mTOR inhibitor treatment
摘要 A method of selection of a patient, who is a candidate for treatment with an mTOR inhibitor (mammalian target of rapamycin inhibitor), whereby to predict an increased or decreased likelihood of response to an mTOR inhibitor, wherein the amino acid at position 1977 of the mTOR protein is determined as being lysine or an adenine is determined as being present at position 5930 of the mTOR gene. The invention provides a method for determining the sequence of mTOR. The method also provides ARMS primers optimised for determining the sequence of mTOR. The invention also provides a diagnostic kit, comprising an ARMS primer. The use of mTOR inhibitors such as rapamycin (sirolimus) is claimed, particularly in cancer treatments.
申请公布号 GB2488028(A) 申请公布日期 2012.08.15
申请号 GB20120002015 申请日期 2012.02.06
申请人 ASTRAZENECA AB 发明人 GAYLE BERNICE MARSHALL
分类号 C12Q1/68;A61K31/436;A61P35/00;G01N33/574 主分类号 C12Q1/68
代理机构 代理人
主权项
地址